We previously showed the involvement of retinoic acid receptor a (RARa) in the induction of tissue-type plasminogen activator (t-PA) synthesis by RA in human umbilical vein endothelial cells (HUVECs). However, the rather slow onset of this induction of t-PA synthesis suggested an indirect role of RARa. Here, we show that the protein synthesis inhibitor, cycloheximide completely blocks the induction of t-PA by RA, which points to the need of an intermediary protein in t-PA stimulation. This intermediary protein is likely to be RARp2 on the basis of the following findings: (1) the induction of RARp by RA exactly precedes that of t-PA; (2) HUVECs EVERAL CLINICAL STUDIES have shown an inverse S correlation between blood fibrinolytic activity and the risk of thromboembolic Consequently, much attention is being paid to the factors that govern blood fibrinolytic activity. Tissue-type plasminogen activator (t-PA), a key enzyme in the initiation of the fibrinolytic process, converts the zymogen plasminogen into the active enzyme plasmin.3 Plasmin can degrade fibrin, the matrix structure of a blood clot, into soluble fibrin degradation products. The importance of the role of t-PA in plasma fibrinolysis has recently been emphasized once more by Carmeliet et a1: who showed that t-PA-deficient mice suffered an impaired thrombolytic potential in combination with an increased susceptibility towards endotoxin-induced thrombosis. The vascular endothelium plays an important role in determining plasma t-PA activity by synthesizing both t-PA and a specific inhibitor, plasminogen activator inhibitor-1 (PAI-1). We and others have previously shown that retinoids, ie, vitamin A and derivatives, rather specifically stimulate t-PA synthesis in cultured human endothelial cells, without markedly influencing PAI-1 synthesis.'.' In vivo studies in rats also show that t-PA levels and retinoid status are ~orrelated.'.'~ Because of their physiological relevance and their potential as a profibrinolytic drug, we are interested in the mechanism(s) by which retinoids stimulate t-PA expression in human endothelial cells.
with elevated RARp mRNA levels show an undelayed t-PA induction on stimulation with RA, and this response can be almost completely inhibited with an RAR antagonist; and (3) an antisense oligodeoxynucleotide against the translation initiation site of RAW2 mRNA greatly reduces the t-PA induction by RA. Thus, induction of t-PA by RA in HUVECs involves a 2-step mechanism requiring induction of RARp2 via RARa, followed by induction of t-PA synthesis via RARp2. Each of these steps is shown to have a different activation profile with RA and 9-cis RA.
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and heterodimeric combinations is possible. Each RAR/RXR subtype combination may specifically control the expression of a subset of RA target genes.14 The question arises whether the induction of t-PA by retinoids in human endothelial cells is also mediated via RARs/ RXRs and, if so, which receptor subtype(s) is involved. In a previous report, we showed by Northern analysis that cultured human umbilical vein endothelial cells (HUVECs) express all three RAR subtypes, RXRa and RXRP, albeit to a widely different extent.' Using subtype-specific ligands and an antagonist with a high preference for RARa, we could identify RARa to be involved in the induction of t-PA by retinoids in HUVECs. However, the rather slow onset of this induction left open the possibility that the role of RARa in t-PA expression is an indirect one. We now show that the induction of t-PA by RA in HUVECs is dependent on ongoing protein synthesis, suggesting that, besides RARa, a second (transcription) factor is required that is not present or is present at levels that are too low under basal conditions. By applying antisense technology, we showed that this factor is likely to be RARP2. Our data are consistent with a 2-step mechanism in which RARa mediates the induction of RARP2, which subsequently mediates the induction of t-PA. On further analysis, each of these steps turned out to have its own ligand-dependency characteristics for RA, which preferentially binds to RARs, and for 9-cis RA, which is a ligand both for RARs and RXRs. in DMSO and stored at -20°C. Stock solutions were diluted with incubation medium to the final test concentrations immediately before the start of an experiment. All experiments involving retinoids were performed in subdued light, and the tubes containing the retinoid solutions were covered with aluminium foil. Sterile, pyrogenfree human serum albumin (20% wt/vol) was from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands). Enzyme immunoassay kits for determination of human t-PA antigen (Thrombonostika t-PA) and PAI-1 antigen ("Imulyse") were obtained from Organon Teknika (Boxtel, The Netherlands) and Biopool (Umel, Sweden), respectively. Ten hours before the start of an experiment, first-passage HUVECs were washed twice with DMEM and then incubated with DMEM supplemented with 20 mmol/L HEPES (pH, 7.4), 0.1 % (wt/vol) human serum albumin, 2 mmol/L L-glutamine, 100 IU/mL penicillin, and 100 pg/mL streptomycin. Subsequently, after a preincubation for 1 hour with 30 pmol/L antisense RARP2 (Fig IB) or control (random or anti RARP4) oligodeoxynucleotides (oligo dNs; Fig IB) , the cells were stimulated with RA (final concentration, I pmol/L) spiked into the medium; the amount of t-PA antigen produced during 12 hours was measured. To ensure the presence of a sufficient amount of antisense oligo dNs during the experiment, a second dose of oligo dNs (30 pmol/L) was added 4 hours after the addition of RA. Antisense oligo dNs were purchased from Isogen Bioscience (Amsterdam, The Netherlands) and were high-performance liquid chromatography-purified.
Total RNA from HUVECs (75 cm') was isolated by the isothiocyanate/phenol/acid extraction method of Chomzynski et a1.I8 The RNA was dissolved in H20, and the RNA concentration was determined spectrophotometrically. Equal
Cell culture experiments.
Antisense experiments. For personal use only. on August 31, 2017. by guest www.bloodjournal.org From L Naz citrate) for 20 minutes and once with 1 X SSC/l% SDS for 20 minutes. The filters were exposed to an Amersham Hyperfilm-MP film with an intensifying screen at -80°C.
Northern blot analysis.
The following cDNA fragments were used as probes in the hybridization experiments: a 1.4-kb BamHI-Xba I fragment of a human RARP cDNA, which was synthesized by polymerase chain reaction (PCR) in the laboratory of Dr P. LeMotte, (Hoffmann-LaRoche, Basel, Switzerland); a 1.9-kb Bgl11 fragment of the human t-PA cDNA'"; and a I .2-kb Pst 1 fragment of a rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (kindly provided by Dr R. Offringa, State University Leiden, The Netherlands).
t-PA antigen and PAI-1 antigen determinations were performed by commercially available immunoassay kits. The enzyme immunoassay for determination of human PAI-I antigen detects active and ''latent'' (inactive) forms of PAI-I, whereas t-PA/ PAI-I complexes are recovered with about 10-fold lower efficiency.
RT-PCR was performed under standard conditions following the specifications recommended by the supplier. The primers used are specified in Fig 1A. In shon, RARP and actin cDNAs were synthesized in one reaction mixture containing 0.25 pg total RNA, 1.6 pg RARP cDNA primer (Fig ]A) , 0.5 pg oligo dN primer and RT-11-superscript (Life Technologies, Paisley, UK); then, the cDNAs were heated for 8 minutes at 95°C. Subsequently, the cDNAs were treated with RNAse H (25 U/mL) for 25 minutes at 37°C. Next, the RARP and actin cDNAs (1 p L of a lox diluted cDNA reaction mixture) were amplified in the presence of 5% (vol/vol) DMSO and 5% W-l (vol/vol; Life Technologies). The amplifications were performed for 30 cycles. The denaturation was performed during 20 seconds at 94°C. Primer extension was performed for 90 seconds at 45°C for the first 5 cycles and at 55°C thereafter. The DNA-synthesizing step was performed at 72°C for 3 minutes. Aliquots of the PCR reaction mixture were separated on an agarose gel, stained with ethidium bromide, and visualized with a UV transilluminator.
For the detection of RARP protein, nuclear extracts were prepared from HUVECs as described previously by Andrews and Faller," with a few modifications. Briefly, cells were washed with phosphate-buffered saline and then allowed to swell on ice for 15 minutes in a buffer containing 10 mmol/L HEPES (pH, 7.9), 1.5 mmol/L MgCI,, 10 mmol/L KCI, 0.5 mmol/L dithiothreitol, and a mixture of proteinase inhibitors (leupeptin, aprotinin, pepstatin, antitrypsin, and chymostatin) at a final concentration of 5 pgimL. Next, the cells were lysed by pushing them through a needle and then were centrifuged at 13,000 rpm in a Microfuge centrifuge for 30 minutes. After resuspending the nuclei pellet in a buffer containing 20 mmollL HEPES (pH, 7.9). 25% (vol/vol) glycerol, 0.42 molL NaCI, I .5 inmoliL MgClz, 0.2 mmol/L EDTA, 0.5 mmol/ L phenylmethylsulfonyl fluoride, 0.5 mmol/L dithiothreitol, and the mixture of proteinase inhibitors (final concentration, 5 pg/mL), the suspension was rotated for 30 minutes at 4°C. Finally, the membranes were pelleted by centrifugation for 5 minutes at 13,000 rpm in the Microfuge centrifuge, and the supernatant was collected. The protein concentration of the supernatant was determined with the Bradford protein assay (Biorad, Munchen, Germmy). Aliquots containing 6 p,g of protein were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis under reducing conditions using a 7.5% (wthol) polyacrylamide gel. Proteins were transferred to nitrocellulose electrophoretically using a semi-dry blotting device. Next the blots were stained with "Ponceau" (Sigma) to check for equal loading and blotting efficiency. The blots were incubated with rabbit polyclonal antibodies raised against the F region of human RARP [RPP(F)2; antibodies kindly provided by Prof P. Chambon, Strasbourg, France). As a second antibody, goat antirabbit antibody (Nordic, Tilburg, The Netherlands) conjugated to horseradish peroxicDNA probes.
Assays.
Reverse trunscriptase-PCR (RT-PCRJ.
Western blotting. dase was used. Detection was performed using the enhanced chemiluminescent detection method (Amershani) according to the manufacturer's instructions. Figure  2 shows one representative time course (of the three performed) of t-PA and RARP mRNA induction in HUVECs treated with 1 pmol/L RA for various periods up to 12 hours. t-PA mRNA levels start to increase after about 8 hours, reaching a 3-fold increase over control levels after 12 hours. Before any exposure to RA, HUVECs express very low levels of two transcripts, 3.2 and 3.4 kb, for RARP. Both transcripts are already increased 6.5-and 7.5-fold, respectively, after 4 hours of incubation with RA and continue to increase to about 1 1 -and 8-fold stimulation, respectively, after 12 hours. As in many other cell types, the expression of RARa, RARy, RXRa, and RXRP in HUVECs did not change appreciably on incubation with RA (see also Kooistra et dY).
RESULTS

Onset of t-PA und RARP mRNA induction by RA.
Effect of protein synthesis inhibition on the induction of t-PA and RARP mRNA by RA. To assess the importance of ongoing protein synthesis on the induction of t-PA mRNA by RA in HUVECs, cells were stimulated with 1 pmol/L RA in the presence of the protein synthesis inhibitor, CHX ( 5 pg/mL; added 1 hour before the start of the experiment). After 8 hours total RNA was isolated and analyzed by Northern blotting. As shown in Fig 3, CHX (which inhibited protein synthesis up to about 95%; data not shown) completely blocked the induction of t-PA mRNA by RA. In contrast, CHX did not prevent the RA-stimulated increase in RARP mRNA. The fact that the induction of RARP by RA is rapid and CHX-resistant is in agreement with findings in other cell types in which it was shown that induction of RARP by RA is directly mediated by RARa." The induction of t-PA apparently requires the synthesis of an intermediary regulatory protein, which explains the slower onset of the t-PA mRNA increase as compared with that of RARP mRNA.
Because the induction profile of RARP preceded that of t-PA (Fig 2) , we examined the possibility that the intermediary factor postulated above is RARP. In a first approach to verify this hypothesis, we designed the following experiment. HUVECs were pretreated for 8 hours with 5 pg/mL CHX and 1 pmol/L RA.
This will lead to an increase in RARP mRNA levels without affecting t-PA mRNA levels (see Fig 3) . If RARP is truly involved in t-PA gene expression, subsequent incubation of these pretreated cells with RA in the absence of CHX should induce t-PA synthesis much faster than it would in control cells, in which RARP first needs to be induced. Moreover, this undelayed t-PA induction in the pretreated cells should be suppressible with an RAR antagonist. As shown in Fig  4 for one representative experiment of three performed, the addition of 10 nmol/L RA to the RA/CHX-pretreated cells resulted in a 5-fold increase in t-PA synthesis during an 8-hour incubation period, whereas this RA concentration had a negligible effect on t-PA production in HUVECs preincubated with control incubation medium. This undelayed t-PA Role of RARP in t-PA induction. induction by RA in the RNCHX-pretreated HUVECs could be largely suppressed by the simultaneous addition of 10 pmoVL Ro 41-5253, a retinoid that antagonizes the transactivation of RARs by RA.I5 Ro 41-5253 also strongly quenched the t-PA production in RNCHX-pretreated HUVECs that were subsequently incubated with control medium, suggesting that the relatively high t-PA production by these cells might be caused by residual RA from the pretreatment period. Therefore, we also evaluated t-PA synthesis in HUVECs pretreated with 5 p g h L CHX alone, a condition also shown to increase RARP mRNAs, albeit to a lesser extent than that in combination with RA (Fig 3) . In this case, incubation of the pretreated cells with control medium hardly For
t-PA synthesis; on addition of 10 nmol/L RA, a qualitatively similar response was observed as that described above for the RNCHX-pretreated cells, ie, a 2.5-fold increase in t-PA production that could be suppressed to a large extent by 10 pmol/L Ro 41-5253. Taken together, these results are consistent with a role of RARP as a mediator of t-PA induction by RA in HUVECs.
Ident$cation of RARB iwfoims. To find more conclusive evidence for a role of RARP in the stimulation of t-PA synthesis by RA, we wished to lower specifically RARP mRNA levels and translation by using antisense oligo dTs. Therefore, it was necessary to identify the RARP isoforms expressed in HUVECs. As shown in Fig 3, RA treatment of HUVECs induces two mRNA transcripts of 3.4 and 3.2 kb in size, respectively. Western blot analysis showed one specific RARP protein band with a molecular weight comparable with that of RARP expressed in transfected COS cells (about 55 kD); the intensity of the RARP band increased after RA treatment of HUVECs (Fig 5A) . Four different isoforms of RARP are known, which only differ in their N-terminal A domain.".24 In contrast to RARPl and RARP3, RARP2 and RARP4 (a spliced variant of RARP2) contain an RA-responsive pr0moter,2'.'~.'' suggesting that the two induced RARP transcripts in HUVECs are the 0 2 and/or P4 isoforms. Application of RT-PCR analysis, which is able to distinguish between the different isoforms (see Fig IC) , showed predominantly the presence and induction of RARP2 mRNA in HUVECs and did not show, or showed only to a minor extent, the presence of RARP4 mRNA (Fig 5B) . Therefore, the two inducible RARP bands observed by Northern blot analysis are likely to predominantly represent two RARP2 transcripts. /L) , RNA was isolated. RARp cDNA was synthesized using 0.25 p g total RNA and a specific RARp primer (see Fig 1A) as described in Materials and Methods. The cDNAs were amplified for 30 cycles using the sense primer 5'-AACTTGGGATCllTCTGGGAACC-3' and antisense primer 5'-CTGGGGAATGllTGAAGTAGCTAG-3' (see also Fig 1A) for 20 seconds at 94°C. for 90 seconds at 45°C in the first 5 cycles and at 55°C in the last 25 cycles, and for 3 minutes at 72°C. The expected length of the PCR fragment of RARpZ is 1641 nucleotides and that of RARp4 is 1286 nucleotides. The data presented are representative of four independent experiments.
Inhibition of RA-stimulated expression of t-PA bv an antisense oligo dN against RAR02 mRNA. Because RARB2 mRNA appeared to be the major form induced by RA in HUVECs, we chose to inhibit RARP levels by an antisense oligo dN directed specifically against the translation start site of RARO2 mRNA, following the protocol described in the Materials and Methods section. Besides blocking transla- tion, binding of such oligo dNs to RARP2 mRNA molecules will make these molecules susceptible to degradation by RNAse H, which will result in a reduction of RARP2 mRNA levels. Figure 6 shows a typical experiment in which antisense oligo dTs directed against RARP2 at a concentration of 30 pmol/L effectively reduced RARP2 mRNA levels, as measured by RT-PCR, whereas a control random oligo dN (Fig IB) did not affect RARP2 mRNA levels. The expression of actin mRNA was included to check for equal efficiency of the RT-PCR procedure between the different samples. As shown in Fig 7A, antisense RARP2 oligo dNs greatly (about 75%) inhibited the increase of t-PA synthesis by RA in HUVECs, whereas random and anti-RARP4 oligo dNs did not affect t-PA induction. As a further control on the specificity of the antisense RARP2 treatment, PAI-I production was determined. PAI-I synthesis appeared not to be affected by any of the antisense oligo dNs used (Fig 7B) . Between experiments with different HUVECs isolates, the efficacy of the antisense oligo dNs directed against RARO2 to reduce RARP2 mRNA levels varied. The reason for this variation is not known at present but may be related to differences in uptake and/or stability of the antisense oligo dNs in different endothelial cell cultures. However, the decrease in t-PA synthesis correlated to the extent of RARP2 suppression (data not shown). Together, these results indicate that the induction of t-PA by RA in HUVECs can be specifically suppressed by using antisense oligo dNs against RARP2.
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Ligand dependency of the RARa-and RARP-mediated steps in t-PA induction. We next addressed the question of whether each of the two steps putatively involved in t-PA induction by RA, namely induction of RARP via RARa followed by t-PA induction via RARP, requires different ligand concentrations for activation. To that end, we assessed the relative potencies of RA, 9-cis RA, and combinations thereof on the induction of RARP2 mRNA in control HUVECs and on the induction of t-PA mRNA in cells with elevated RARP levels by pretreatment with CHX. As shown in Fig SA, for an 8-hour incubation period, RA and 9-cis RA were equipotent in inducing RARP mRNA; both compounds required a minimal concentration of 100 nmol/L to induce RARP mRNA, and induction levels increased to about 9-fold stimulation at 1 pnol/L with both ligands. A combination of the two isomers showed at least an additive effect on the expression of RARP mRNA at suboptimal concentrations but never exceeded the maximal stimulation induced by either RA or 9 4 s RA alone. At supramaximal concentrations ( I O pmol/L RA or a combination of 1 pmol/L RA and 1 pmol/L 94.7 RA), RARP mRNA induction levels decreased again. In contrast to the induction of RARP, RA had already induced t-PA mRNA strongly at concentrations as low as 10 nmol/L in CHX-pretreated cells, and this response was only slightly more increased at concentrations of I pmol/L (Fig SC) . 9-cis RA was much less effective than RA. At least IO-fold higher concentrations of 9 4 7 RA were required to achieve comparable induction of t-PA mRNA. In general, RA in combination with 9-cis RA was not more effective than RA alone in enhancing t-PA mRNA induction. These results indicate that each of the two steps involved in t-PA mRNA induction responds differently to (combinations of) different concentrations of RA and 9 4 s RA, and that RA and 9-cis RA are not equipotent in inducing t-PA expression.
DISCUSSION
In a previous study, we have reported on the involvement of RARa in the induction of t-PA gene expression by RA in HUVECs.' However, the relatively slow action of RA on t-PA gene expression suggested a mechanism in which the induction of t-PA is a secondary response to activation of RARa by RA. We now provide evidence that a second step is indeed necessary and involves the synthesis of RARP2 on the basis of the following findings: ( I ) the kinetics of the RA-associated increase in RARP mRNA are consistent with the subsequent involvement of RARP in the regulation of t-PA: (2) the effect of RA on the induction of t-PA, but not that of RARP, was completely abolished by the protein synthesis inhibitor, CHX: (3) HUVECs with elevated RARP mRNA levels as a result of pretreatment of the cells with RA and/
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or CHX showed an undelayed increase in t-PA expression by RA that could be quenched by the RAR antagonist Ro 41-5253; and (4) antisense oligo dNs directed against RARO2 greatly suppressed the induction of t-PA by RA. Taken together, these results point to a 2-step mechanism in which RARP2 is first induced via RARa and then RARP2 mediates the induction of t-PA. Experiments with different concentrations of RA and 9-cis RA showed that each step has a different ligand dependency.
Complementary to our studies, Bulens et al" identified a functional RARE in the t-PA promoter, consisting of a direct repeat of the GGGTCA motif spaced by 5 nucleotides (DR5) and localized at -7.3 kb. Transient expression of a 2-kb RARE-containing t-PA promoter:CAT construct into the hybrid endothelial cell line EA.hy926 resulted in a 6-fold in- duction by RA, whereas no induction was observed with a reporter construct in which the t-PA DR5 RARE was eliminated by site-specific mutagenesis. A maximal induction by RA of this RARE-containing t-PA promoter:CAT construct in the endothelial cell line required cotransfection with RARP-and RXRa-expressing plasmids. Our results in combination with those of the study by Bulens et all3 provide strong evidence that RARP2 is the ultimate mediator of t-PA induction by RA in HUVECs.
A 2-step mechanism as described above for the induction of t-PA by RA in HUVECs is not unique in itself for retinoidinduced genes. For example, similar observations were made with some retinoid-responsive genes in F9 cells, such as laminin B I , collagen IV, and 56 genes.'" These genes were induced after a relatively long (12 to 24 hours) exposure to retinoids, and their induction was also sensitive to CHX. Also, the relatively slow action of RA on transferrin and albumin gene expression in Hep3B cells (8 to 24 hours) may be a secondary response to RA." Several factors have been shown to serve as an intermediary protein in the RA response, including c-jun, GATA-binding proteins, and nuclear factor KB heterodimers.'X.3" However, the number of RA-responsive genes whose induction is known to be mediated by an RAR as a secondary protein, such as the t-PA induction in HUVECs in this study, is still rather limited. To our knowledge, only the induction of major histocompatibility complex class I in NTera-2 embryonal carcinoma cells has been shown to be at least partly dependent on the RAinduced increase of RARfl.30
Our results do not exclude the possibility that, in addition to RARP2, other factors are required for the induction of t-PA by RA. Several reports have provided evidence that members of the steroidlthyroid receptor superfamily, including retinoid receptors, require cofactors for transcription activation. For example, Folkers and Van der Saag" have shown that the adenovirus EIA protein functions as a cofactor for RARP-mediated activation of transcription. Also, functional interactions of peroxisome proliferator-activated receptor, RXR, and SPI in the transcriptional regulation of the acylcoenzyme-A oxidase promoter have been shown." Whether RARP2 also requires a cofactor for induction of t-PA by RA is uncertain. However, it may be significant, as discussed by Bulens et all3 that, in the vicinity of the RARE in the t-PA promoter, several SPI and AP2 consensus binding sites are present.
Our results support initial suggestions that the various RAR subtypes may preferentially control the transcription of different subsets of RA-responsive genes. This concept was based on two types of observations: (1) the striking interspecies amino acid sequence conservation of a given RAR (and RXR) isoform, which is much higher than the similarity between the three RAR (or the three RXR) isoforms within a given species"; and (2) the specific spatiotemporal patterns of expression for each RAR (and RXR) gene as shown by in situ hybridization studies on embryo sections.""' More direct evidence came from cotransfection experiments in which each of the RAR and RXR isoforms showed some specificity towards several synthetic and natu- 
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ral R A R E s .~~ Also, in a different type of study, targeted disruption of RARa in F9 cells resulted in reduced cellular RA-binding protein 11 (CRAPBPII) and Hoxbl mRNA expression in RA-stimulated cells." However, it has been found that a certain degree of redundancy may exist in the retinoid-signaling pathway. For example, knock-out mice for all RARa isoforms showed a phenotype that is relatively discrete considering the ubiquitous expression of RARa,"' and knock-out mice for specific isoforms studied so far (RARaI, RARP2, and RARy2) have no apparent phenotype.")4' Similarly, some of the natural promoters that have been tested in cotransfection experiments could be activated, albeit to different extents, by more than one RAR or RXR form?' Also in the case of t-PA, Bulens et a!" showed that RARa, RARP, and RXRa were all able to stimulate a 2.4-kb RARE-containing t-PA promoter fragment linked to a For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
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CAT reporter gene in cotransfection experiments in HT1080 fibrosarcoma cells, although RARP in combination with RXRa gave maximal stimulation in these experiments. However, in these studies transfected cells have been used expressing concentrations of RARs/RXRs at nonphysiologically high levels. Therefore, these transfection experiments do not necessarily imply that the same regulatory mechanisms hold true under physiological conditions; ie, restricted receptor expression is one mechanism of specifying gene activation by hormones. Our results obtained in HUVECs indicate that, in a physiological context, RARa specifically induces RARP2 and that the RAR subtype P 2 is involved in the induction of t-PA, which points to a preference of different RAR subtypes to induce different target genes.
It is assumed that, in the cellular context, RARs act predominantly as heterodimers with RXRs.4' Our results shown in Fig 8 show that RA and 9-cis RA are equipotent in stimulating RARP expression in HUVECs and that a combination of both ligands never is more effective than each compound alone at optimal concentration. For the induction of t-PA in HUVECs with elevated RARP levels, RA is even much more effective than 9 4 s RA. Because RA acts mainly via binding to RARs, whereas 9-cis RA can bind to and activate both RARs and R X R S ,~.~~ ligand binding to RXR, if occurring, does not substantially contribute to the two transactivation steps. In line with this conclusion, we found A remarkable finding was the observation that higher concentrations of RA are required for the stimulation of RARP expression, which involves RARa activation, than for the induction of t-PA expression, which involves RARP activation. Binding studies with purified RARa and RARP preparations show equal affinity of both receptors for RA.46.49 In agreement with our findings, Brand et a15" also reported a 10 times higher apparent affinity of RA for RARP than for RARn in a cellular system. A similar discrepancy between data from binding studies with purified receptors and data from cell studies exists for RA and 9-cis RA in relation to RARP. Our results show that 9-cis RA is less potent in inducing t-PA than is RA, although binding studies using isolated receptors show similar binding affinities of RA and 9-cis RA for RAR,0.46,49 Apparently, cellular factors influence the binding affinities of retinoids for their receptors.
Our observation that RARP transcripts in HUVECs are upregulated by retinoid treatment is not just a cell culture phenomenon, because both a 3.3-kb and a 3.0-kb RARP mRNA are increased within 1 to 4 hours in lung and liver tissues from retinol-deficient rats receiving a single dose of RA (100 pg)." However, under normal physiological conditions, RA concentrations in plasma and tissues are sufficient to maintain a steady RARP e x p r e s~i o n .~~ Also, because of the high affinity of RARP for RA (Brand et also and this study), it seems that the capacity of RA to stimulate t-PA synthesis in vivo is almost fully exploited under normal physiological conditions. In line with this finding, plasma t-PA activity in vitamin A-deficient rats is about %fold lower than control values, whereas RA treatment of normal rats increases plasma t-PA activity maximally by only 50%.1° Similarly, treatment of male volunteers with isotretinoin ( 13-cis RA), which has been shown to induce t-PA levels in HUVECS,~ did not effect or only minimally effected t-PA antigen in p l a~m a .~"~~ Therefore, attempts to increase plasma t-PA levels by the use of retinoids should be directed at finding RARP-specific ligands with a higher transactivation capacity than that of RA, rather than at increasing plasma RA levels.
Taken together, our results provide evidence that the induction of t-PA synthesis by RA in HUVECs occurs via a 2-step process in which one receptor subtype, RARa, is required for the induction of a second subtype, RARD2, that subsequently mediates t-PA synthesis. These apparently subtype-specific functions of RARs in HUVECs are accompanied by a different ligand dependency of each step; whereas RA and 9-cis are equipotent in inducing RARP, RA shows a much higher efficacy than 9-cis RA in inducing t-PA synthesis in cells with elevated RARP levels.
